MTRR rs1801394 and its interaction with MTHFR rs1801133 in colorectal cancer: a case–control study and meta-analysis. (July 2017)

• Record Type: Journal Article
• Authors: Haerian, Monir Sadat; Haerian, Batoul Sadat; Molanaei, Saadat; Kosari, Farid; Sabeti, Shahram; Bidari-Zerehpoosh, Farahnaz; Abdolali, Ebrahim
• Is Part Of: Pharmacogenomics. Volume 18:Number 11(2017)
• Page Start: 1075
• Page End: 1084
• Publication Date: 2017-07
• Subjects: colorectal cancer -- meta-analysis -- MTHFR -- MTRR -- polymorphism -- susceptibility; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2017-0030
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: This study aims to evaluate the association between the MTRR rs1801394 alone or in interaction with the MTHFR rs1801133 and susceptibility to colorectal cancer (CRC) and its characteristics in Iranian population. Additionally, both a systematic review and meta-analysis were performed to derive a more precise assessment of this association.Materials & methods: Genomic DNA of 2332 subjects was genotyped for rs1801394. These data were pooled with 17 eligible studies for meta-analysis.Results: No significant association was found between the rs1801394 or rs1801394-rs1801133 and CRC risk. Meta-analysis results also demonstrated no significant relationship between the rs1801394 and CRC risk.Conclusion: Results of this study showed that the rs1801394 alone or together with the rs1801133 is not a risk factor for CRC in Iranian population.